Type 1 diabetes Type 1 diabetes
Conditions
Interventions
5000 individuals with type 1 diabetes >
18 years of age, visiting the outpatient clinic of Diabeter center Amsterdam and DiabeterNederland.
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Everyone with type 1 diabetes above the age of 18
Exclusion criteria
Exclusion criteria: 1. Active infection during the study visit 2. Inability or unwillingness to donate feces or urine. 3. Smoking or illicit drug use (e.g. MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or useduring the study period. 4. Inability or unwillingness to provide informed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints: The primary endpoint is long-term residual ß-cell function as assessed by baseline and stimulated2-hour post meal urinary C-peptide levels at 3,6 and 10 years follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint pertains presence and incidence of diabetes complications (cardiovascular disease, nephropathy,neuropathy and retinopathy), gut microbiota composition measured in feces with shotgun sequencing, glucose time-in-range (CGM-metrics) and subsequent exogenous insulin dose. Tertiary endpoints include the profiling of immune cell subsets, assessment ofautoreactive T lymphocytes and HLA typing by high resolution sequencing of circulating leukocytes (IMMOCHIP) in relation tountargeted plasma metabolomics (Metabolon). | — |
Countries
Netherlands
Contacts
Public ContactM Nieuwdorp
Amsterdam UMC
Outcome results
None listed